August 17, 2007 – C. R. Bard Inc. announced that it has received FDA approval to market its FLAIR Endovascular Stent Graft to treat stenoses (narrowing) at the venous anastomosis of synthetic arteriovenous (AV) grafts in hemodialysis patients to increase blood flow.